ReviewBiomolecules & therapeutics2023
Structural Insights for β-Lactam Antibiotics.
Review in Biomolecules & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Biodegradation Characteristics of Piperacillin by Marine Bacillus cereus PP1 and Genome-Guided Mining of Candidate β-Lactamases.Functional & integrative genomics · 2026Article
- Antibiotics modulate activity of mouse and human dorsal root ganglia neurons.bioRxiv : the preprint server for biology · 2026Article
- Structural and Dynamics Analyses of β-Lactam Inhibition ofACS chemical biology · 2026Article
- Concise construction of β-branched aromatic D-amino acids via transaminase-catalyzed dynamic kinetic resolution.Nature communications · 2026Article
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Molecular basis of ampicillin resistance: combinatorial mechanisms and future strategies.World journal of microbiology & biotechnology · 2026Review
- Joining Forces Against Antibiotic Resistance in Aquaculture: The Synergism Between Natural Compounds and Antibiotics.Antibiotics (Basel, Switzerland) · 2026Review
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Structural comparison of substrate-binding pockets of serine β-lactamases in classes A, C, and D.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Integrated experimental and computational study reveals enhanced antimicrobial efficacy of amoxicillin loaded in oleic acid nanoemulsion against multidrug-resistantRSC advances · 2025Article
- In-Silico discovery of novel cephalosporin antibiotic conformers via ligand-based pharmacophore modelling and de novo molecular design.Journal, genetic engineering & biotechnology · 2025Article
- Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC medicinal chemistry · 2025Review
- Assessing the Antibiotic Resistance in Food Lactic Acid Bacteria: Risks in the Era of Widespread Probiotic Use.Food science & nutrition · 2025Review
- Development andRSC advances · 2025Article
- Phenotypic and Genotypic Characterization of ESBL andAntibiotics (Basel, Switzerland) · 2025Article
- Pectobacterium versatile β-Lactamase Contributes to Soft Rot Pectobacteriaceae (SRP) Community Diversity During Potato Infection.Environmental microbiology reports · 2025Article
- CombattingAntibiotics (Basel, Switzerland) · 2025Review
- A quality by design HPLC method for cephalosporin analysis in pharmaceuticals and water samples with environmental impact assessment.Scientific reports · 2025Article
- Endolysin NC5 improves early cloxacillin treatment in a mouse model of Streptococcus uberis mastitis.Applied microbiology and biotechnology · 2024Article
- Green Fabrication of Silver Nanoparticles, Statistical Process Optimization, Characterization, and Molecular Docking Analysis of Their Antimicrobial Activities onto Cotton Fabrics.Journal of functional biomaterials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance has emerged as a global threat to modern healthcare systems and has nullified many commonly used antibiotics. β-Lactam antibiotics are among the most successful and occupy approximately two-thirds of the prescription antibiotic market. They inhibit the synthesis of the peptidoglycan layer in the bacterial cell wall by mimicking the D-Ala-D-Ala in the pentapeptide crosslinking neighboring glycan chains. To date, various β-lactam antibiotics have been developed to increase the spectrum of activity and evade drug resistance. This review emphasizes the three-dimensional structural characteristics of β-lactam antibiotics regarding the overall scaffold, working mechanism, chemical diversity, and hydrolysis mechanism by β-lactamases. The structural insight into various β-lactams will provide an in-depth understanding of the antibacterial efficacy and susceptibility to drug resistance in multidrug-resistant bacteria and help to develop better β-lactam antibiotics and inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.